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Multiple chromosomal regions are affected by deletions in cervical cancer (CC) genomes, but their consequence and target
gene involvement remains unknown. Our single nucleotide polymorphism (SNP) array identified 8p copy number losses
localized to an 8.4 Mb minimal deleted region (MDR) in 36% of CC. The 8p MDR was associated with tumor size, treat-
ment outcome, and with multiple HPV infections. Genetic, epigenetic, and expression analyses of candidate genes at MDR
identified promoter hypermethylation and/or inactivation of decoy receptors TNFRSF10C and TNFRSF10D in the majority
of CC patients. TNFRSF10C methylation was also detected in precancerous lesions suggesting that this change is an early
event in cervical tumorigenesis. We further demonstrate here that CC cell lines exhibiting downregulated expression of
TNFRSF10C and/or TNFRSF10D effectively respond to TRAIL-induced apoptosis and this affect was synergistic in combi-
nation with DNA damaging chemotherapeutic drugs. We show that the CC cell lines harboring epigenetic inactivation of
TRAIL decoy receptors effectively activate downstream caspases suggesting a critical role of inactivation of these genes in
efficient execution of extrinsic apoptotic pathway and therapy response. Therefore, these findings shed new light on the
role of genetic/epigenetic defects in TRAIL decoy receptor genes in the pathogenesis of CC and provide an opportunity to
explore strategies to test decoy receptor gene inactivation as a biomarker of response to Apo2L/TRAIL-combination
therapy. VC 2015 Wiley Periodicals, Inc.
INTRODUCTION
Genetic studies identified the short arm of chro-
mosome 8 (8p) as a frequent target of nonrandom
and recurrent deletion in cervical cancer (CC)
(Mitra et al., 1994; Hampton et al., 1996; Harris
et al., 2003; Bhattacharya et al., 2004; Rao et al.,
2004; Kloth et al., 2007; Ojesina et al., 2014).
These studies suggest the presence of tumor sup-
pressor genes on 8p and their involvement in the
development of CC. However, until now the bio-
logical impact or the relevant deregulated genes
and the mechanisms underlying 8p deletion has
not been known. 8p deletions also have been fre-
quently implicated in multiple other tumor types
including prostate, liver, kidney, bladder, and
colorectal carcinomas (Chang et al., 2007; Berou-
khim et al., 2009; Midorikawa et al., 2009;
Williams et al., 2010), and a number of tumor
suppressor genes have been suggested such as
NKX3-1, tumor necrosis factor-related family of
genes (TNFRSF10C, TNFRSF10D), NRG1,
UNC5D, ARHGEF10, DLC1 (Macartney-Coxson
et al., 2008; Xue et al., 2008; Chua et al., 2009),
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indicating that one or more genes residing on 8p
are commonly involved in a wide-variety of tumor
types.
Despite the advances in early detection, CC
remains a major cause of cancer deaths in women
worldwide due to treatment failure of invasive
cancer (Waggoner, 2003). CC progresses by dis-
tinct morphological changes from normal epithe-
lium to carcinoma through grades of squamous
intraepithelial lesions (SILs). While infection of
high-risk human papilloma viruses (HPVs) is rec-
ognized as an important etiologic agent in cervical
pathogenesis, other genetic alterations are needed
for the progression (zur Hausen, 2002). To date,
no genetic markers are available to predict
response to treatment of invasive CC. Therefore,
identification of critical “somatic genetic hits” in
CC is important in understanding its biology and
establishing clinically relevant biomarkers.
In this study, we identified recurrent 8p dele-
tions in invasive CC and inactivation of decoy
receptors TNFRSF10C and TNFRSF10D as major
target genes at this region. We demonstrate that
inactivation of decoy receptors elicits synergistic
TRAIL-Cisplatin induced cell death through
extrinsic apoptotic pathway in the presence of
DNA-damaging drugs. Additionally, the promoter
hypermethylation of TNFRSF10C occurs very
early during the tumor progression suggesting a
role for this gene in CC development.
MATERIALS AND METHODS
Patients, Tumor Tissues, and Cell Lines
A total of 264 samples of DNA representing var-
ious stages of CC progression were used in this
study. These include 123 invasive CC (nine cell
lines and 114 primary tumors), 141 cytological pap
smears from normal and precancerous lesions. The
cell lines HT-3, ME-180, CaSki, MS751, C-4I, C-
33A, SW756, HeLa, and SiHa were obtained from
American Type Culture Collection (ATCC) and
grown in culture as per the supplier’s specifica-
tions. All specimens were obtained from Columbia
University Medical Center (NY), Instituto Nacio-
nal de Cancerologıa (Bogota, Colombia), and the
Department of Gynecology of Campus Benjamin
Franklin, Charite-Universit€atsmedizin Berlin
(Germany) with appropriate informed consent and
approval of protocols by institutional review
boards (Narayan et al., 2003b). All primary tumors
were diagnosed as squamous cell carcinoma but
six that were diagnosed as adenocarcinoma. Clini-
cal information such as age, stage, and size of the
tumor, follow-up data after initial diagnosis and
treatment were obtained for the majority of
tumors from the review of institutional medical
records. Tissues were frozen at 2808C im-
mediately after resection and were embedded
with tissue freeze medium (OTC) before macro-
dissection. All primary tumor specimens were
determined to contain at least 60% tumor by
examination of hematoxylin and eosin staining of
adjacent sections. Cytological specimens were
collected and processed as reported previously
(Narayan et al., 2009). Thirty-four pap smears
diagnosed as normal, 22 as atypical squamous cells
of undetermined significance (ASC-US), 43 as
low-grade SIL (LSIL), and 42 as high-grade SIL
(HSIL) were analyzed. The diagnosis of all HSILs
was also confirmed by a biopsy. High-molecular
weight DNA from frozen tumor tissues, cell lines,
and cell pellets from cytology smears was isolated
by standard methods. HPV types were identified
as described earlier (Narayan et al., 2003a).
SNP Array and Fluorescence
In Situ Hybridization Analysis
The Affymetrix 250K NspI SNP chip was used
for copy number analysis as per the manufacturer’s
protocol. SNP array was performed on 80 CC
specimens (9 cell lines and 71 primary tumors)
selected based on high tumor content and 7 mac-
rodissected normal cervical squamous epithelia as
controls. Acquisition and analysis of copy number
data for chromosome 8 using CytoBand informa-
tion files from the dChip website (http://biosun1.
harvard.edu/complab/dchip/chromosome.htm#ref-
gene) was performed as described (Scotto et al.,
2008a,b). Copy numbers <1.5 were considered as
deletion, 2.5–4.0 as gain, and >4.1 as amplification
in the raw copy number view.
Affymetrix U133A array (Santa Clara, CA) was
hybridized using RNA from 42 CC cases (33 pri-
mary tumors enriched by macrodissection and 9
cell lines) and 20 macrodisssected normal cervical
squamous epithelial cells using the standard proto-
cols (Li and Wong, 2001; Lin et al., 2004; Scotto
et al., 2008a; Scotto et al., 2008b) (GEO accession
numbers: GSE9750 and GSE10092). A total of 671
probe sets on Chr8 were present in U133A array
representing 6% of the genome (2.4% on 8p). To
obtain differentially expressed gene signatures, we
compared all normal with all tumor samples
using the criteria of 1.75-fold change between the
group means at 90% confidence interval and a
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significance level of P <0.05. All negative expres-
sion values for each probe set were truncated to 1
before calculating fold changes and <10% of sam-
ples with present call in each group were
excluded. The differentially expressed probe list
was used in all subsequent supervised analyses
using the same criteria between various groups to
obtain relevant gene signatures.
Fluorescence in situ hybridization (FISH) anal-
ysis was performed by standard methods using
BAC clones (RP11-875O11 and RP11-109B10)
that span the 8p21 common region of deletion and
centromere 8 as control.
Methylation-Specific polymerase chain reaction
(PCR) and Sequencing
Tumor and control DNAs were treated with
sodium bisulphite as described (Narayan et al.,
2003a). Primer sets used for amplification of methyl-
ated and unmethylated DNA spanning the CpG
Island of promoter regions are shown in Supporting
Information Table 1. Additional primer set spanning
32 CpG sites at 2149 to 1222 bp in relation to tran-
scription start site of the TNFRSF10C cDNA clone
NM_003841, and the sequence common to both
methylated and unmethylated templates was used
for cloning and sequencing (Supporting Information
Table 1). PCR was performed using standard condi-
tions for 30 cycles on primary invasive cancer and 35
cycles for precancerous lesions with annealing tem-
peratures varying between 56 and 628C. PCR prod-
ucts were run on 2% agarose gels and visualized
after ethidium bromide staining. All methylation-
specific PCR (MSP) experiments were performed in
triplicate, and the promoter hypermethylation was
considered positive when present in replicate experi-
ments. MSP products were subcloned into pCR2.1-
TOPO vector (Invitrogen) followed by sequencing
of multiple clones using M13 primers.
Drug Treatment
Cells in culture were treated with 5-mM 5-Aza-
20deoxycytidine (5-aza dC) (Sigma-Aldrich) for 5
days by replacing the medium daily, trichostatin
(Sigma-Aldrich) at a final concentration of 200 nM
for 24 hr and a combination of both as described
(Narayan et al., 2009). Human recombinant
TRAIL (Invitrogen) dissolved in distilled water,
Actinomycin D (Invitrogen) dissolved in DMSO,
Cisplatin (LKT laboratories) dissolved in N,N-
dimethylformamide were used at the indicated
concentrations and exposure times. By testing sev-
eral concentrations on CC cell lines, we found 500
ng/ml each of TRAIL and Actinomycin D as opti-
mal for detecting cell death. We determined
ICD50 value of Cisplatin by testing concentrations
from 0.5 to 50 mg/ml, which varied from 2.5 to 16.0
mg/ml in cell lines used in this study, except SW-
756 that was resistant even at 50 mg/ml (Support-
ing Information Fig. 1). Based on this, we used 3-
mg/ml final concentration of Cisplatin.
Reverse Transcription Polymerase Chain Reaction
(RT-PCR) and Western Blot Analyses
Total RNA from normal cervical squamous epi-
thelium (three from commercial sources and five
from hysterectomy specimens), tumor tissues, and
cell lines was reverse transcribed as described
elsewhere (Narayan et al., 2003a). Relative quanti-
tation of expression of NKX3-1 (Assay ID
Hs00171834) and Human GAPDH as endogenous
control (FAM/MGB Probe) genes was performed
in triplicate experiments using TaqMan Gene
Expression Assay using the Applied Biosystems
7500 Fast Real-Time PCR system (Foster City,
CA). Semiquantitative expression of TNFRSF10A,
TNFRSF10B, TNFRSF10C, TNFRSF10D, and
NKX3-1 was performed in duplicate RT-PCR
TABLE 1. Frequency of Promoter Hypermethylation of Decoy Receptor Genes in CC Progression
TNFRSF10C TNFRSF10D
Tissue type No. studied Methylated (%) No. studied Methylated (%)
Normal cervix 34 0 ND ND
ASC-US 22 5 (22.7) ND ND
LSIL 43 8 (18.6) ND ND
HSIL 42 5 (11.9) ND ND
Primary invasive cancer 114 48 (42.1) 114 5 (4.4)
CC cell lines 9 8 (88.9) 9 2 (22.2)
All Invasive cancer 123 56 (45.5) 123 7 (5.7)
ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepi-
thelial lesion; ND, not done.
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experiments using the primers shown in Support-
ing Information Table 1 and standard thermal
cycle conditions. Immunoblot analysis was per-
formed by standard methods using the antibodies
for DR4, DR5, DcR1 and DcR2 (Thermo
Scientific, Pierce), CASP8, CASP9, CASP10 (Cell
Signalling Technology), and CASP3 (BD Trans-
duction Laboratories). Secondary antibody conju-
gated with horseradish peroxidase was obtained
from Santa-Cruz Technology. Blots were reprobed
with ß-actin as control. Detection was performed
by ECL-Western Lightning Chemiluminescence
reagent (Amersham Pharmacia).
Mutation Analysis
Sanger sequencing was performed to identify
mutations on DNA amplified using the two sets of
primers spanning exons 1 and 2 of NKX3-1 gene
(Supporting Information Table 1).
Cell Survival and Apoptosis Analysis
Cell viability and cytotoxicity against TRAIL
and other drugs was assessed by standard 3-(4,5-
dimethylthiazol-2-yl)22,5-diphenyltetrazolium
bromide (MTT; Invitrogen) colorimetric assay.
Briefly, 5,000 cells were seeded in 96-well-cell cul-
ture plate, grown overnight at 378C in 5% CO2,
treated with indicated concentrations of drugs for
24 hr. After incubation of cells in 5 mg/ml of
MTT in phosphate buffer saline for 3.5 hr, the
dye was dissolved in 150 ml of MTT solvent and
the optical density of solubilized formazan was
assessed using microplate reader (BioTek Quant).
All treatments were performed in four replicate
wells and repeated three times.
To measure apoptosis, we used Pacific BlueTM
Annexin VSYTOXVR AADvancedTM Apoptosis
Kit (Invitrogen). Briefly, one million cells were
seeded in 6-well-tissue culture plates, grown over-
night at 378C at 5% CO2 incubator, replaced with
new culture medium and added the indicated
concentration of drugs. Cells collected after 16 or
24 hr of incubation were analyzed by LSR II flow
cytometry (BD Biosciences) using 405 and
488 nm excitation and 455 and 647 nm emission.
A total of 20,000 events were analyzed using
Flowjo software (Tree Star, OR) in duplicate
experiments.
Statistical Analysis
ANOVA and t-test statistics were calculated
using the GraphPad Prism software (LaJolla, CA).
RESULTS
Identification of 8p12-21.3 Minimal Deleted Region
and Candidate Downregulated Genes in CC
SNP array analysis of 71 primary tumors and 9
cell lines identified copy number alterations
(CNA) on chromosome 8 in 38 (47.5%) cases,
losses in 30 (37.5%), and gains in 23 (28.8%) cases.
Gains were frequently seen on 8q and the losses
on 8p. Amplification at 8q24.12 was seen in a sin-
gle case. Analysis of the dataset with losses on
chromosome 8 showed monosomy in three cases
and partial deletion in 27 cases (Fig. 1A). Among
the tumors that exhibited partial deletions, losses
on 8p were only seen in 16 (53.3%) cases, on both
chromosomal arms in 10 (33.3%) cases, and only
on 8q in one case. Overall, 8p was affected by
deletion in 29 of 30 (96.7%) of all the deleted
cases, suggesting 8p is the frequent target of dele-
tion in CC. To identify common minimal deleted
region (MDR) on 8p, we examined the SNP data
for smaller regions of loss. Notably, we found 2
cases (T-117 and T-194) defining the MDR on 8p.
The MDR was involved in all cases with 8p dele-
tions, except 3 (Fig. 1A), which spans an 8.4 Mb
region between 22,941 and 31,338 kb genomic
interval on chromosome 8p. All cell lines that had
8p deletion by SNP array were also showed
decreased copies by FISH using a probe spanning
the MDR, except in HeLa cell line (data not
shown). HeLa cell line showed most part of chro-
mosome 8 loss except distal 8q gain, while the
FISH did not reveal relative decrease of 8p21
region compared to control centromere probe.
Based on these results, we hypothesized that
this decreased 8p genomic dosage results in loss of
function of one or more genes relevant to CC
tumorigenesis. The 8p12-21.3 MDR contains 92
probe sets comprising 53 known genes. To exam-
ine the consequence of 8p deletion on gene
expression, we used gene expression profiling of
chromosome 8 probe dataset from Affymetrix
U133A array on 20 normal (age range, 27–64 year;
mean6 standard deviation (SD)5 46.96 7.6) squa-
mous epithelial samples (including the seven sam-
ples used in SNP array), 33 primary tumors (age
range 28–70 year, mean6 SD5 48.96 12.3; 22 of
these tumors were also analyzed by SNP array), and
9 cell lines (all analyzed by SNP array). To identify
differentially expressed gene signatures of 8p MDR
in CC, we performed supervised analyses using the
92 probe set between tumors and normal, and
between 8p deleted and undeleted tumors using the
criteria described in methods. This analysis identified
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only NKX3-1 as a down regulated gene in tumors
compared to normal (Fig. 1B). Among the cell
lines studied, 7 of 8 had 8p MDR and all cell lines
showed NKX3-1 downregulated expression includ-
ing C-33A that did not show 8p deletion. Of the
22 primary tumors studied by both SNP and
U133A arrays, all 9 tumors that showed 8p dele-
tions had downregulated expression and 12 of 13
tumors that did not show 8p deletion also showed
decreased expression of the NKX3-1. Therefore,
no correlation of NKX3-1 downregulation with 8p
deletion was found suggesting other mechanisms
may play a role in its inactivation. Furthermore,
we ruled out promoter methylation or mutations
as potential mechanisms of downregulated expres-
sion (Supporting Information Fig. 2 and data not
shown).
A family of four TNFRSF10 genes
(TNFRSF10A, TNFRSF10B, TNFRSF10C, and
TNFRSF10D) that play role in apoptosis map to
the MDR at 8p21. Expression of none of the
three genes (TNFRSF10B, TNFRSF10C, and
TNFRSF10D) present on U133A array showed a
complete correlation with 8p deletion. However, a
high frequency of tumors (29/42, 69%) showed
downregulated expression of TNFRSF10D com-
pared to normal (Fig. 1B). Therefore, this inte-
grative analysis did not identify a candidate target
downregulated gene as a consequence of 8p
deletion.
To further examine the significance of 8p dele-
tion, we evaluated its association with clinical
parameters such as age, stage, and size of the
tumor, treatment outcome, and HPV type by uni-
variate analyses. 8p deletions were found to be sig-
nificantly associated with tumor size (10% cases in
<5 cm vs. 36% in >6 cm; P5 0.04), outcome of
the treatment (18.2% patients were alive or with
complete remission vs. 39.4% of patients died of
disease between 1 and 72 month follow up), and
multiple HPV infections (63.6% in multiple HPV
infections vs. 28.9% in HPV16 alone cases).
Although not statistically significant, Kaplan–
Meier survival analysis showed a 2-fold risk of
death in patients carrying 8p deletions (Fig. 1C).
These findings thus suggest that 8p deletion may
serve as a predictor of clinical outcome to conven-
tional therapies.
Figure 1. Genetic analysis of 8p deletion in CC. (A) Identification
of 8p12-21.3 minimal deletion by 250K NspI SNP array. Each vertical
column represents a sample with genomic regions representing from
pter (top) to qter (bottom) on chromosome 8. Prefix “T” indicates
primary tumor; “CL” indicates cell line. The blue–red scale bar (21 to
11) at the bottom represents the copy number changes relative to
mean across the samples. The intensities of blue and red indicate rela-
tive decrease and increase in copy numbers, respectively. G-banded
ideogram of chromosome 8 is shown on the extreme right. All tumors
that exhibited chromosome 8 losses are shown from largest to small-
est region of deletion. Inferred copy number view of T-194 showing 8p
minimal deletion from normal (2N) (red line) is shown on right. (B)
Gene expression using U133A array and analysis of genes mapped to
MDR in CC cell lines and primary tumors. Significantly differentially
expressed genes were identified by comparing normal, cell lines and
primary tumor groups. In the matrix, each row represents the gene
expression relative to group mean and each column represents a sam-
ple. The genes are shown on right. The scale bar (22 to 12) on the
bottom represents the level of expression with intensities of blue rep-
resents decrease and red for increase in expression. (C) Kaplan–Meier
curves showing survival differences between 8p deleted and undeleted
cases.
TRAIL DECOY RECEPTOR INACTIVATION AND THERAPY RESPONSE IN CERVICAL CANCER 181
Genes, Chromosomes & Cancer DOI 10.1002/gcc
Promoter Hypermethylation-Mediated
Inactivation of Decoy Receptor Genes
at 8p12-p21.3 MDR
TNF receptor superfamily decoy receptor genes
are known to be epigenetically inactivated in mul-
tiple tumor types (Shivapurkar et al., 2004). As
stated above, the 8p MDR contains a cluster of
four TNFRSF10 family genes. TNFRSF10C
(DcR1) and TNFRSF10D (DcR2) act as potentially
antiapoptotic genes since they lack active death
domains, whereas TNFRSF10A (DR4) and
TNFRSF10B (DR5) act as proapoptotic genes
(Gonzalvez and Ashkenazi, 2010). Based on their
function, these genes might be potential targets of
8p MDR. To understand their role, we examined
the promoter hypermethylation status of these
genes in 123 invasive cancers (9 cell lines and 114
primary tumors) by MSP analysis. Promoter meth-
ylation was identified in TNFRSF10C and
TNFRSF10D, while it was absent in TNFRSF10A
and TNFRSF10B. Hypermethylation of
TNFRSF10C was found in 56 (45.5%) of the 123
CC cases (cell lines, 88.9%; primary tumors,
42.1%; Table 1). The other decoy receptor
TNFRSF10D showed promoter hypermethylation
in 5.7% tumors. DNA isolated from 34 normal cer-
vical epithelia did not reveal hypermethylation in
these promoters. To validate the MSP data, we
performed bisulfite sequencing of a region cover-
ing 32 CpGs within the CpG island of
TNFRSF10C in one unmethylated and five meth-
ylated primary tumors, chosen randomly to repre-
sent each of these classes, along with the controls
confirmed the MSP results (Fig. 2A).
Of the 9 cell lines studied, 8 were MSP positive
for TNFRSF10C without evidence for the pres-
ence of an unmethylated allele. These data com-
bined with SNP array (Fig. 1A) suggest that 7 of 8
cell lines with 8p deletion had methylation of the
second allele. The remaining cell line (MS751)
that harbor 8p deletion by SNP array did not show
promoter methylation of TNFRSF10C. The C-33A
cell line that had disomy for chromosome 8p by
SNP array exhibited both methylated alleles.
Therefore, these data supports that TNFRSF10C
is one of the targets of chromosome 8p deletion.
Thus, the cell line data suggest that the
TNFRSF10C inactivation follow the “two-hit”
hypothesis (Knudson and Strong, 1972). However,
only 9 of 21 (43%) primary tumors showed simul-
taneous loss of 8p and TNFRSF10C promoter
methylation. Similarly, 18 (36%) of 50 tumors
Figure 2. Analysis of TNFRSF10C methylation and expression in CC.
(A) Bisulphite MSP cloning and sequencing. U, unmethylated; M, meth-
ylated. CpG sites examined are numbered sequentially as shown
above. Filled circles indicate methylated CpG sites and empty circles
indicate unmethylated CpGs. Each row represents a clone and each
panel represents a tumor or control. (B) and (C) RT-PCR analysis of
TNFRSF10C and TNFRSF10D in CC. (B) Box plot showing semiquantita-
tive analysis in normal, primary tumors and CC cell lines. ANOVA,
normal versus tumor, not significant; normal versus cell line P< 0.0001,
significant. (C) Box plot showing semiquantitative analysis in normal,
unmethylated, and methylated tumors. ANOVA, normal versus unme-
thylated, not significant; normal versus methylated P< 0.0004, signifi-
cant. Box plots show median, 25th and 75th percentile, minimum and
maximum values. (D) Immunoblot analysis showing expression of
TNFRSF10 receptors. Actin was used as a loading control. (E) Effect of
drug treatment using inhibitors of methylation and HDAC on gene
reactivation by RT-PCR analysis in CC cell lines. Bracketed M and UM
indicates methylated and unmethylated cell lines, respectively. ACTB,
beta actin; U, untreated; A, 5-Aza-20-deoxycytidine; T, TSA; A/T, 5-Aza-
20-deoxycytidine and TSA.
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without 8p deletion also showed promoter methyl-
ation. Therefore, no strict association between
methylation and 8p deletion could be established
in primary tumors.
Since the TNFRSF10C expression using U133A
array was unclear in relation to 8p deletion, we
extended the expression studies using real time
RT-PCR to examine if aberrant promoter hyper-
methylation is associated with transcriptional down-
regulation. TNFRSF10C expression on a panel of 20
normal cervical epithelia, 9 CC cell lines, and 25
tumor specimens showed no significant downregu-
lation relative to ß-actin between primary tumors
(mean6 SD5 0.816 0.33) and normal epithelium
(mean6 SD5 0.946 0.15). However, the expres-
sion in the cell lines (mean6 SD5 0.366 0.34) was
significantly decreased compared to normal
(P< 0.0001) and primary tumors (P5 0.0017; Fig.
2B). Further analysis to examine the relationship
between methylation and gene expression showed
significant differences in TNFRSF10C levels
between normal and methylated tumors (mean-
6SD5 0.586 0.40; P< 0.0004), while no differ-
ence between normal and unmethylated tumors
(mean6 SD5 0.996 0.11; P5 0.48) was found.
Similarly, the expression levels were also signifi-
cantly (P5 0.004) lower in methylated tumors com-
pared to unmethylated tumors (Fig. 2C). Thus, the
RT-PCR data suggest that promoter hypermethyl-
ation of TNFRSF10C results in transcriptional
downregulation. Furthermore, western blot analysis
of cell lines showed all methylated cell lines exhib-
ited decreased protein levels of TNFRSF10C,
while the unmetylated cell line (MS751) expressed
high levels of protein (Fig 2D). For TNFRSF10D
gene, six of the 9 cell lines showed relatively low
protein. Two of 3 methylated cell lines and four of
6 unmethylated cell lines showed decreased levels
of TNFRSF10D protein (Fig. 2D). Of note,
TNFRAF10A showed relative low levels of protein
in four of 9 cell lines, while TNFRSF10B showed
no detectable decrease. Overall, these data suggest
that promoter methylation or other epigenetic
mechanisms results in downregulation of TRAIL
decoy receptors in the majority of CC cell lines.
To examine the role of DNA hypermethylation
and histone modifications in gene silencing, we
treated eight methylated and one unmethylated
cell lines with 5-aza dC and TSA. RT-PCR analy-
sis of these cells showed various levels of reactiva-
tion of TNFRSF10C and with Aza or Aza with
TSA treatments, but not with TSA alone, in all
methylated cell lines. However, no reactivation
was found in unmethylated cell line MS751 (Fig.
2E). These data confirm that the methylation of
TNFRSF10C promoter results in downregulated
expression and demethylation effectively reacti-
vates the gene expression by reversing the methyl-
ation affect.
To examine the prognostic role of TNFRSF10C
hypermethylation, we performed a correlative
analysis of methylation with clinicopathologic fea-
tures such as age, tumor stage, and size of the
tumor, clinical outcome, and HPV type in primary
tumors and found no significant associations (data
not shown).
DNA Damaging Agents Cisplatin and Actinomycin
D Sensitizes TRAIL Mediated Apoptotic Response
in 8p-Deleted CC Cell Lines
TNF-related apoptosis-inducing ligand or
Apo2L (TRAIL) binds to its agonistic receptors
triggering apoptosis. TRAIL therapy is evaluated
as a promising tool in several cancer clinical trails.
However, the efficacy of TRAIL varies among
tumors owing to defects in death-inducing signal-
ing complex (DISC) formation. Since 8p deleted
CC cases showed adverse outcome to standard
therapies, we examined if the efficiency of
TRAIL-induction of apoptosis is 8p deletion
dependent. Treatment of TRAIL showed higher
apoptotic response in 8p-deleted cell lines (SiHa,
C-4I, CaSki, SW-756, HeLa, ME-180, HT-3, and
MS-751) compared to an undeleted cell line (C-
33A) (P5 0.0002; Fig. 3A, lane 1). Exposure to
antineoplastic DNA-intercalating agents Cisplatin
or Actinomycin D significantly increased apoptosis
in 8p-deleted cell lines compared to undeleted
cell line (Fig. 3A, lanes 2 and 3). To examine
whether these drugs enhance the TRAIL-
mediated apoptosis, we tested TRAIL combined
with Cisplatin or Actinomycin D, and identified a
synergistic effect by both the drugs showing sig-
nificant increase in 8p-deleted cell lines (Fig. 3A,
lanes 4 and 5). Although the differences were less
significant by cytotoxicity assays (Supporting
Information Fig. 3) these results indicate that 8p
deletion effectively enhances lethality of Cisplatin
or Actinomycin D combination with TRAIL treat-
ment in CC cells.
Epigenetic Inactivation of Decoy Receptor
Expression Effectively Mediates TRAIL-Induced
Apoptosis
Since 8p-deleted CC cells are sensitive to
TRAIL-induced apoptosis and TRAIL mediated
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apoptotic response depend on the balance of
expression of its death receptor (DR4 and DR5)
and antagonistic decoy receptor (DcR1 and DcR2)
genes, we next want to elucidate the role of decoy
receptor inactivation in drug response. Of the 8
cell lines that showed 8p deletion, four (SiHa, C-
4I, SW-756, MS-751) had normal levels of
TNFRSF10D expression, while the remaining four
(CaSki, HeLa, ME-180, HT-3) showed decreased
expression (Figs. 1B and 2D). We found that treat-
ment of TRAIL alone or combined with Cisplatin
or Actinomycin D showed a significantly high apo-
ptosis and reduced cellular viability in cell lines
with decreased expression of TNFRSF10D com-
pared to the cell lines that expressed normal levels
of TNFRSF10D (Fig. 3B and Supporting Informa-
tion Fig. 3B). The cell line (ME-180) that showed
8p deletion and TNFRSF10D methylation also
showed high-apoptotic response and sensitivity to
cell death as compared to 8p deleted but
TNFRSF10D unmethylated cell lines (Fig. 3C,
Supporting Information Figs. 3C and 4). The cell
lines (C-33A and ME-180) that exhibited
TNFRSF10D methylation showed a similar sensi-
tivity to cell death irrespective of 8p deletion sta-
tus (Fig. 3D and Supporting Information Fig. 3D).
These data, thus, suggest that TRAIL-induced
cell death response is dependent on either the sta-
tus of methylation and/or the levels of expression
of TNFRSF10D. This affect was synergistic in the
presence of Cisplatin or Actinomycin D (Fig 3,
Supporting Information Fig 3).
We then examined changes in TNFRSF10C
gene in response to these drugs. When compared
CC cell lines with the combination of 8p deletion,
promoter methylation with down regulated
expression (SiHa, C-4I, CaSki, SW-756, HeLa,
ME-180, and HT-3) and an unmethylated with
Figure 3. Decoy receptor inactivation is a positive biomarker in
mediating TRAIL-induced apoptosis in CC cell lines. Cells were treated
with indicated drugs and concentrations for 2 hr. The percent total
cell death was measured as sum of Annexin V positive, Annexin V/
SYTOX AADvanced double positive and SYTOX AADvanced positive
cells using Annexin V/SYTOX AADvanced kit (Invitrogen) and FACS
analysis. (A) Comparison of cell death between with or without 8p-
deleted CC cell lines. (B) Analysis of cell death in relation to
TNFRSF10D expression levels in 8p deleted CC cell lines. (C) Analysis
of cell death in relation to TNFRSF10D methylation in 8p-deleted CC
cell lines. (D) Analysis of cell death in relation to TNFRSF10D methyla-
tion independent of 8p deletion in CC cell lines. (E) Analysis of cell
death in relation to TNFRSF10C methylation and expression in 8p-
deleted CC cell lines. (F) Analysis of cell death in relation to
TNFRSF10C methylation and expression independent of 8p deletion in
CC cell lines. Statistically significant differences are indicated at the top
for each group.
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normal levels of expression (MS-751), the data fur-
ther revealed that the unmethylated cell line
exhibits resistance to cell death to TRAIL- and
other combination drug treatments. This effect
was significantly synergistic to TRAIL combined
with Cisplatin or Actinomycin D (Figs. 3E and 3F,
Suppl Figs. 3E, 3F, and 4).
Therefore, these in vitro experiments establish
that the tumor cells carrying a combination of
methylated alleles and/or downregulated transcrip-
tion of one or both decoy receptors elicit efficient
antitumor effects against TRAIL-combination
treatments.
Epigenetic Inactivation of Decoy Receptors
Facilitates Efficient Activation of Extrinsic
Apoptotic Pathway
Since we observed enhanced cell death
response to TRAIL-combination drug treatments
in cell lines expressing low levels of DcR1 and
DcR2, as well as apoptotic resistance in cell line
expressing low level of death receptor DR4, we
wanted to examine the relation between receptor
expression, and caspase activation to TRAIL-
Cisplatin treatments. To test this, we chose four
cell lines with variations in decoy receptor methyl-
ation/downregulated expression exhibiting
extreme sensitivity or resistance to TRAIL/Cispla-
tin treatment. ME-180 cells carrying promoter
hypermethylation/inactivation of DcR1 and 2 as
well as normal expression of death receptors was
the cell line that exhibited maximum response to
TRAIL, Cisplatin, or Actinomycin treatments.
Upon treatment of ME-180 cells with TRAIL,
Cisplatin, or combination of both resulted in acti-
vation of initiator CASP8. However, other initiator
caspase CASP10 showed no evidence of activation
(Fig. 4). The effector caspase CASP3 is also highly
activated after treatment with TRAIL combined
with Cisplatin (Fig. 4). Of note, in addition
CASP9 that plays a role in mitochondrial apoptotic
pathway, is also activated. These data thus suggest
active apoptotic pathway in this cell line. In
Figure 4. Activation of extrinsic apoptotic pathway after TRAIL-
Cisplatin combination treatment in CC cell lines depends on the meth-
ylation/inactivation status of TRAIL receptors. Western blot analysis
showing Caspase-8, caspase-9, caspase-3, caspase-10, DR4, DR5, DcR-
1, DcR-2, and TP53 expression after treatment with Cisplatin, TRAIL,
or combination of both. Cleaved fragments with molecular size
markers are shown on the right in kDa. These results confirmed on at
least 3 independent experiments. Right panel: Western blot analysis
showing activation of caspases-8, 29, and 23 in ME180 cell line;
caspase-8 and 29 activation in MS751 cell line. Left panel showing lack
of caspase activation in C-4I (only caspase-8 activated) and C-33A cell
lines.
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addition, proapoptotic receptor DR4 levels were
elevated after treatment with Cisplatin alone or in
combination with TRAIL, while DR5 levels
remain unchanged. Thus the TRAIL1Cisplatin
treatment activates DR4 leading to active caspase
pathway in this cell line (Fig. 4). Thus, we assume
that the inactivated decoy receptors in ME-180
facilitate high sensitivity to cell death via extrinsic
apoptotic signaling. A second cell line C-4I with
promoter methylation associated inactivation of
DcR1 that also exhibited high rate of cell death
after the drug treatment, showed activation of only
initiator caspase, 8, but no detectable activation of
downstream caspases CASP3 or 9 was found.
Treatment did not result in any detectable
changes in DR4 or DR5 levels in this cell line.
Therefore, high sensitivity to TRAIL/Cisplatin
resulting in activated caspase pathway in ME-180
is due to concomitant inactivation of both decoy
receptors. However, the second cell line C4-I that
also exhibits high sensitivity to TRAIL did not
effectively activate downstream caspases. Since
only one decoy receptor is inactivated in this cell
line, other alternative pathways such as mitochon-
drial pathway may also play role in sensitizing the
these cells. Of note, TP53 is activated on treat-
ment with Cisplatin or Cisplatin combined with
TRAIL in C-4I supporting TP53-dependent path-
way may be active.
The MS751 cell line carrying unmethylated pro-
moters and detectable levels expression of DcR
genes exhibited highest resistance to TRAIL/Cis-
platin. Treatment of this cell line with TRAIL/
Cisplatin results in activation of caspases 8 and 9,
but no evidence of CASP3 activation was found.
Thus, this finding suggests defective activation of
caspase pathway in this cell line (Fig. 4). A second
cell line C-33A despite downregulated expression
of both DcR genes was resistant to TRAIL/Cispla-
tin treatment (Fig. 4). No evidence of caspase acti-
vation was seen in this cell line after treatment.
This cell line carries TP53 mutation and exhibits
complete lack of DR4 expression. Thus, the apo-
ptotic resistance in this cell line is due to DR4
absence and possibly TP53 also plays a role in
resistance, which may override the advantage con-
ferred by decoy receptor inactivation promoting
cell death response. Thus, these data suggest that
decoy receptor inactivation promotes cell death
response to TRAIL-Cisplatin treatment, in the
presence of active death receptors, by activating
the caspases that play role in extrinsic apoptotic
pathway.
TNFRSF10C Promoter Hypermethylation Occurs
at an Early Stage in CC Development
To identify the role of promoter hypermethyl-
ation of TNFRSF10C gene in CC progression, we
studied methylation status in DNA obtained from
141 cytological smears diagnosed as normal
(N5 34), ASC-US (N5 22), LSIL (N5 43), or
HSIL (N5 42). We found no evidence of methyla-
tion in DNA from cytologic smears diagnosed nor-
mal. In contrast, 5 (22.7%) of 22 cases diagnosed
as ASC-US, 8 (18.6%) of 43 LSILs and 5 (11.9%)
of 42 HSILs showed promoter hypermethylation
by MSP analysis (Table 1). Thus, these data pro-
vide evidence that promoter hypermethylation of
TNFRSF10C initiate at an early developmental
stage during CC tumorigenesis.
DISCUSSION
Chromosome arm 8p suffers frequent deletions
in many human epithelial and hematologic malig-
nancies (http://cgap.nci.nih.gov/Chromosomes/
RecurrentAberrations). Here, we show that the
8p12-21.3 as the MDR in CC and the deletion
prognosticates a 2-fold increased risk of death.
Therefore, it is likely that one or more
proliferation-regulated genes are situated in the
deleted region and their inactivation plays a role
in CC. The MDR at 8p12-21.3 contains a number
of genes known to play a role in human cancer. In
this study, we identified TNFRSF10C and
TNFRSF10D spanning the MDR as target inacti-
vated genes by genetic and/or epigenetic
mechanisms.
The proteins encoding TNFRSF10C and
TNFRSF10D belongs to the TNF-receptor fam-
ily containing an extracellular TRAIL-binding
domain and a transmembrane domain, but lacks
the cytoplasmic death domain. Thus, these recep-
tors are not capable of inducing apoptosis.
Although DcR1 and DcR2 express on cell surface
lack functional intracellular death domain, they
are fully functional. DcR1 and DcR2 inhibit
TRAIL-induced apoptosis by competing with
proapoptotic TRAIL receptors DR4 and DR5 in
binding TRAIL, thus act as antagonistic molecules
that protect cells from TRAIL-induced apoptosis
by preventing the assembly of death-inducing sig-
naling complex (DISC) (Sheridan et al., 1997;
Micheau and Merino, 2004). TNFRSF10C and
TNFRSF10D genes have been shown to be inacti-
vated by promoter hypermethylation in multiple
tumor types (van Noesel et al., 2002; Shivapurkar
et al., 2004; Yang et al., 2007; Hornstein et al.,
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2008; Braga Lda et al., 2012; Mahapatra et al.,
2012). Here, we identified functional inactivation
of TNFRSF10C and TNFRSF10D in a high propor-
tion of CC by promoter hypermethylation or
downregulated expression as shown by the previ-
ous reports (Shivapurkar et al., 2004, 2007). Thus,
the decoy receptor inactivation identified in this
study suggests that TRAIL-induced apoptosis
may be an effective treatment option in patients
exhibiting inactive TNFRSF10C and/or
TNFRSF10D combined with the conventional
chemoradiotherapy in CC. Although TRAIL-
induced apoptosis is a promising approach in can-
cer therapy, not all tumors are sensitive to TRAIL.
The mechanisms involved in TRAIL resistance
are not fully understood. One postulated mecha-
nisms have been that overexpression of DcR1 or
DcR2 protect tumor cells from TRAIL-induced
apoptosis (Sheridan et al., 1997). In this study, we
have demonstrated that inactive DcR1 and DcR2
genes can enhance TRAIL-mediated apoptosis in
CC. Our studies further suggest that combination
of chemotherapeutic agents such as Actinomycin
D or Cisplatin with TRAIL are highly effective in
achieving increased TRAIL-induced apoptosis in
tumor cell lines with 8p deletion or inactivated
DcR1 and DcR2 genes. Thus, our data demonstrate
that patients carrying 8p deletion and/or decreased
expression of decoy receptors in their tumor cells
may benefit from combination chemotherapeutic
drugs with recombinant TRAIL. Many previous
studies focused on mechanisms of TRAIL resist-
ance and the mechanisms of tumor sensitivity are
largely ignored. This study demonstrates that at
least one of the mechanisms of sensitivity is decoy
receptor downregulation. However, a better
understanding of biologic mechanisms underlying
tumor response with logical combination of drugs
in CC is needed to identify and enrich responsive
patient selection.
Combination therapies can affect more than one
death pathways. For example, expression of
TRAIL receptors and their decoy receptors can be
induced by wild-type TP53 and other transcription
factors upon treatment with DNA damaging
agents (Takimoto and El-Deiry, 2000; Liu et al.,
2005). Thus, the DNA damaging agents such as
chemotherapy and radiation can be more effective
in combination with TRAIL and synergistic effect
has been demonstrated in a number of tumor
types (Mahalingam et al., 2009).
Since TRAIL receptors are TP53-regulated
DNA damage-inducible genes, mutations in TP53
may impair TRAIL-induced apoptotic activity
(Ruiz de Almodovar et al., 2004; Liu et al., 2005).
The majority of CC are HPV 16 positive, where
high-risk HPV E6 protein causes TP53 degrada-
tion, and hence nonfunctional. In this scenario, it
is expected that the HPV16-positive cervical
tumors may have impact on TRAIL therapy
response. The present data in relation to HPV
infection and TP53-mutated CC cell lines showed
that TP53-mutated tumors exhibited slightly
higher resistance to TRAIL, but the difference
were not statistically significant between HPV
positive and negative cell lines (Supporting Infor-
mation Figs. 5A and 6A). This is consistent with
nonfunctional TP53 in mutated and HPV-negative
cell lines, while HPV-positive tumors may still
express low levels of functional TP53 and exhibit
slightly higher response to TRAIL. Our data sug-
gest that HPV-negative tumors carrying TP53
mutations may be more resistant to TRAIL ther-
apy. Whether the type of high-risk HPV deter-
mines response to TRAIL and combination with
DNA damaging agents is not known. Our in vitro
data showed that the tumors carrying HPV 16 and
HPV18/45 exhibited significantly higher resistance
to TRAIL and combination with Actinomycin D
or Cisplatin compared to cell lines carrying HPV
18, 16/18, 39/68 (Supporting Information Figs. 5B–
5F and 6B–6F). However, these observations and
the mechanisms of TRAIL resistance in relation
to HPV infection remain to be validated further in
a larger series of cell lines.
Synergy between DNA damaging agents and
TRAIL has been well established in a variety of
tumors (Morizot et al., 2011). Our present in vitro
studies provide evidence that decoy receptor inac-
tivation potentially enhances antitumor efficacy of
TRAIL by activating the extrinsic death pathway.
However, the relative contribution of signals that
trigger apoptosis by TRAIL sensitization depends
on large variety of events ranging from DISC for-
mation to more distal events. CFLAR, regulator of
apoptosis structurally similar to caspase-8 and a
critical molecular at DISC formation, is one such
gene. CFLAR downregulation of either full length
or short variants have been shown to either induce
or reduce TRAIL-induced apoptosis (Irmler et al.,
1997). We have previously reported that the chro-
mosomal region that maps CFLAR was deleted in
both precancerous and cancerous lesions of cervix,
and its downregulation in cell lines (Narayan
et al., 2003b). Although TRAIL-Cisplatin
inducted caspase activation correlate with inactiva-
tion of decoy receptor genes, the activation of cas-
pases is highly variable. One mechanism, as has
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been shown in C-33A cell line, is that lack of DR4
expression fails to activate the extrinsic pathway.
Downstream pathway gens such as CFLAR
remains to be assessed for their role in activation
of caspases. Thus, further analysis of downstream
pathway genes may clarify the mechanisms of
TRAIL sensitivity and/or resistance in CC.
In this study, we also identified TNFRSF10C
promoter methylation in all grades of precancerous
lesions (Table 1). The potential of individual cer-
vical precancers to progress to higher grades is cur-
rently unpredictable (Syrjanen, 1996; McCredie
et al., 2008; Schiffman and Rodriguez, 2008).
Whether the TNFRSF10C methylation and the
associated inactivation will serve as a potential sig-
nature in defining risk of progression or even serve
as biomarker of treatment of precancerous lesions
remains to be understood and warrants further
studies.
TNFRSF10C promoter methylation was found
in 23% of specimens with ASC-US diagnosis. A
cytological diagnosis of ASC-US is reported in
around 5% of women undergoing Pap screening
but the clinical relevance of ASC-US is largely
unclear. Follow-up studies of patients with this
unequivocal diagnosis show histologically high-
grade disease (CIN) lesions or even invasive can-
cer in a proportion of cases (The ASC-US-LSIL
Triage Study (ALTS) Group, 2003). However, no
optimal strategy for ASC-US triage to identify
high-grade disease that requires follow-up and
treatment is available in limiting the number of
women who receive unnecessary procedures.
Since we found TNFRSF10C methylation in 23%
patients with the diagnosis of ASC-US, whether
these patients represent already underlying high-
grade disease remains to be determined.
In conclusion, our present results clearly dem-
onstrate that patients with detectable 8p12-21.3
deletion harboring multiple tumor suppressor
genes are at risk for disease progression and poor
outcome. We identified inactivation of
TNFRSF10C and TNFRSF10D in majority of CC
cases. We also demonstrated that cell lines with
inactivated DcR1 and DcR2 showed enhanced
TRAIL-induced cell death in combination drug
therapy by efficient activation of extrinsic apopto-
tic pathway. Therefore, it is anticipated that
patients that lack expression of decoy receptors
may display enhanced response to TRAIL-
combination therapies. Strategies that down-
modulate decoy receptors might also be a viable
approach for an affective TRAIL therapy in CC
patients.
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